New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

Impact · against what's priced in

The biomarker data for Taltz and Zepbound provides scientific validation for a combined therapy strategy, but it does not meaningfully shift the valuation of LLY. The market is already pricing in GLP-1 dominance and high revenue growth; a specific commercial strategy for the 61% of psoriasis patients with obesity is a marginal incremental gain compared to the primary drivers of production capacity and oral pill penetration.

LLY+0.10

Not in the price yet

The price assumes